SP
BravenNow
Edwards Lifesciences CVP Bobo sells $2m in stock
| USA | economy | ✓ Verified - investing.com

Edwards Lifesciences CVP Bobo sells $2m in stock

#Edwards Lifesciences #Insider Trading #Stock Sale #Donald Bobo #NYSE:EW #Medical Devices #Corporate Executive #52-week High

📌 Key Takeaways

  • Edwards Lifesciences CVP Donald E. Bobo Jr. sold $2 million worth of company stock
  • The sale occurred as the stock trades near its 52-week high
  • Recent earnings showed revenue beating expectations but EPS falling short
  • Stifel maintains Buy rating with $110 price target despite stock appearing overvalued

📖 Full Retelling

Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences Corp (NYSE:EW), sold 24,000 shares of company stock on February 25, 2026, realizing approximately $2 million in proceeds as the medical device company's shares trade near their 52-week high. The transactions, executed at prices ranging from $83.66 to $83.96 with a weighted average price of $83.8365, totaled $2,012,076. This insider sale occurred as Edwards Lifesciences stock approached its 52-week high of $87.89, with shares trading at $85.90 at the time of reporting, while InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value. Following the transaction, Bobo directly owns 21,266.2532 shares of Edwards Lifesciences, while maintaining indirect holdings of 38,900.5862 shares through a 401(k) plan and an additional 121,756 shares held in trust. The company carries a market cap of $49.8 billion and trades at a P/E ratio of 47.36. This insider transaction comes amid mixed financial results for the company, as Edwards Lifesciences recently reported fourth-quarter 2025 earnings with adjusted earnings per share of $0.58, falling short of analysts' expectations of $0.62. However, the company posted revenue of $1.57 billion, surpassing the consensus forecast of $1.55 billion and reflecting an 11.6% year-over-year growth. Despite the earnings miss, Stifel has reiterated its Buy rating for Edwards Lifesciences, setting a price target of $110.00. The company also announced an expansion of its Every Heartbeat Matters initiative, aiming to help 2 million more patients access structural heart treatment by 2030, building on the program's impact of over 4 million underserved patients globally since its inception in 2014.

🏷️ Themes

Insider Trading, Medical Devices, Stock Market Performance, Corporate Finance

📚 Related People & Topics

Edwards Lifesciences

American biotechnology company

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium...

View Profile → Wikipedia ↗
Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗
Medical device

Medical device

Device to be used for medical purposes

A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the d...

View Profile → Wikipedia ↗

Entity Intersection Graph

No entity connections available yet for this article.

Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain This is where Deutsche Bank sees silver prices ending the year Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Edwards Lifesciences CVP Bobo sells $2m in stock By Investing.com Insider Trading Published 02/26/2026, 09:22 PM Edwards Lifesciences CVP Bobo sells $2m in stock 0 EW 2.99% Donald E. Bobo Jr., CVP, Strategy/Corp Development at Edwards Lifesciences Corp (NYSE:EW) , sold 24,000 shares of common stock on February 25, 2026. The shares were sold at a weighted average price of $83.8365, resulting in a total transaction value of $2,012,076. The prices for the transactions ranged from $83.66 to $83.96.The sale comes as Edwards Lifesciences stock trades near its 52-week high of $87.89, with shares currently at $85.90. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. The medical device company carries a market cap of $49.8 billion and trades at a P/E ratio of 47.36. Following the transaction, Bobo directly owns 21,266.2532 shares of Edwards Lifesciences Corp. He indirectly owns 38,900.5862 shares through a 401 and 121,756 shares by trust. For deeper insights, InvestingPro offers 9 additional exclusive tips and comprehensive analysis for Edwards Lifesciences. In other recent news, Edwards Lifesciences reported its fourth-quarter 2025 earnings, revealing an adjusted earnings per share of $0.58, which fell short of analysts’ expectations of $0.62. However, the company posted a revenue of $1.57 billion, surpassing the consensus forecast of $1.55 billion, indicating an 11.6% year-over-year growth. Stifel has reiterated its Buy rating for Edwards Lifesciences, setting a price target of $110.00, following these financial results. Additionally, the company announced an e...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine